Octreoteva Long Acting (Octreotide Acetate)

Octreotide acetate is used in several endocrine‑related conditions where inhibition of hormone secretion is required.

• Acromegaly: reduces excessive growth hormone production and helps control disease activity.
• Neuroendocrine tumors: controls hormone‑related flushing and diarrhea associated with carcinoid syndrome.
• VIPoma and other functional pancreatic tumors: decreases vasoactive intestinal peptide secretion and mitigates severe watery diarrhea.

• Octreotide acetate mimics natural somatostatin, binding with high affinity to somatostatin receptor subtypes (particularly sst2 and sst5). This interaction inhibits adenylate cyclase activity, reduces cyclic AMP formation, and suppresses the release of various hormones and peptides, leading to decreased secretion of growth hormone, insulin, glucagon, and gastrointestinal peptides.

Adverse reactions to Octreotide acetate may vary in frequency and severity.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal cramping, or pain.
• Injection site reactions: erythema, swelling, or induration.
• Gallbladder abnormalities: biliary sludge or gallstones.
• Hyperglycaemia or hypoglycaemia: altered blood glucose levels.
• Headache or dizziness.

Serious or Rare Side Effects

• Pancreatitis: inflammation of the pancreas.
• Severe hypersensitivity: anaphylaxis or severe skin reactions.
• Cardiac arrhythmias: irregular heart rhythms.
• Acute cholecystitis: inflammation of the gallbladder.
• Severe hyperglycaemia requiring medical intervention.

Before initiating therapy with Octreotide acetate, clinicians should assess patient‑specific factors and monitor for potential complications.

• Cardiovascular assessment: evaluate for pre‑existing arrhythmias or heart disease.
• Glycaemic monitoring: check blood glucose regularly, especially in diabetic patients.
• Gallbladder surveillance: perform periodic imaging to detect sludge or stones.
• Drug interactions: review concomitant medications that affect glucose or cardiac function.
• Pregnancy and lactation: weigh potential benefits against risks; use only if clearly needed.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide acetate can influence the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Insulin or oral hypoglycaics: may require dose adjustment due to altered glucose control.
• Cytochrome P450 substrates metabolised by CYP3A4: risk of increased exposure.

Moderate Interactions (Monitor Closely)

• Somatostatin analog‑containing regimens: additive hormonal suppression.
• QT‑prolonging agents: potential for enhanced cardiac repolarisation effects.
• Anticoagulants: monitor clotting parameters as gastrointestinal effects may alter absorption.